Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
نویسندگان
چکیده
منابع مشابه
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
OBJECTIVES Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices. Using data on exports of raw materials in 2015, we calculated currently feasible generic prices of sofosbuvir and daclatasvir. METHODS Data on per-kilogram prices of sofosbuvir and daclatasvir a...
متن کاملSofosbuvir and daclatasvir
After entering hepatocytes, the viral genome of the hepatitis C virus (HCV) is translated into a single polypeptide. This polypeptide is subsequently cleaved into viral proteins, including non-structural (NS) proteins NS3, NS4A, NS5B and NS5B RNA dependent RNA polymerase (Figure 1) [3, 4]. These viral proteins are essential for viral replication and assembly making them significant targets for ...
متن کاملAsunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation.
AIM This study aimed to clarify the efficacy and safety of interferon-free therapy using asunaprevir and daclatasvir, or sofosbuvir and ledipasvir for post living donor liver transplantation (LDLT) recipients with hepatitis C virus (HCV). METHODS A retrospective cohort study of LDLT recipients with HCV genotype 1b treated with asunaprevir (100 mg twice daily) and daclatasvir (60 mg once daily...
متن کاملReal-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting. This study aimed to evaluate the efficacy and safety of generic sofosbuvir/ledipasvir (SOF/LDV) in a real-life clinical experience. Methods: ...
متن کاملSofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-H...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Virus Eradication
سال: 2016
ISSN: 2055-6640
DOI: 10.1016/s2055-6640(20)30691-9